Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

Kidney fibrosis is a hallmark of chronic kidney disease yet is poorly treated. Chang et al. determined that plasma and kidney levels of the vascular growth factor, angiopoietin-2, were elevated in patients with chronic kidney disease and mice with kidney disease. Angiopoietin-2 inhibited the renoprotective effects of angiopoietin-1 and promoted CC chemokine ligand 2–mediated kidney damage, endothelial cell apoptosis, vascular rarefaction, inflammation, fibrosis, and kidney dysfunction. Hence, therapeutically inhibiting angiopoietin-2 may represent a novel means of treating these chronic kidney disease–associated pathologies.

Original languageEnglish
Pages (from-to)691-694
Number of pages4
JournalKidney International
Volume102
Issue number4
DOIs
Publication statusPublished - Oct 2022

Cite this